drugset / Trial / NCT06323395

Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye

NCT06323395 ↗

RandomizedParallel-groupTriple-blindSupportive care

Summary

The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S Lipid Balance, a new eye drops, emulsion developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to severe evaporative DED after a treatment for 30 days.

Timeline

Start
2022-06-01
Primary completion
2022-12-01
Completion
2022-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Vizol S LIPID BALANCE Unknown 1 unknown Topical

Indications